Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04933890 · ClinicalTrials.gov registry record
Detection of Heart Conditions Using Artificial Intelligence
A clinical trial, sponsored by Eko Devices.
- Completed
- Registry status
- 68
- Enrollment target
NCT04933890: Completed study, sponsored by Eko Devices.
NCT04933890 is a clinical trial that has completed, run by Eko Devices. The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04933890 has completed, sponsored by Eko Devices.
- COMPLETED
- Registry status
- 68 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate how Eko AI performs in the real world, front-line setting where the availability of sophisticated, expensive diagnostic tools is limited, and where there is a premium on detecting VHD early in its course.
Primary Outcome
Evaluate performance of single-lead ECG based algorithm to identify individuals with reduced ejection fraction.
Interventions
- DEVICE Use of Eko DUO electronic stethoscope
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2021-12-31 |
What the finished NCT04933890 record still lists
NCT04933890 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 68 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Use of Eko DUO electronic stethoscope is the first listed.
NCT04933890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04933890 about?
NCT04933890 is a clinical study titled "Detection of Heart Conditions Using Artificial Intelligence". The purpose of this study is to evaluate how Eko AI performs in the real world, front-line setting where the availability of sophisticated, expensive diagnostic tools is limited, and where there is a premium on detecting VHD early in its course.
What is the current status of trial NCT04933890?
This trial is currently completed. The enrollment target is 68 participants. The study started on 2021-06-01. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT04933890?
The interventions under investigation include: Use of Eko DUO electronic stethoscope (DEVICE).
Who is sponsoring clinical trial NCT04933890?
This trial is sponsored by Eko Devices, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI